Multiple clinical trials are currently underway examining the possible synergistic effects of combining chemotherapy with immunotherapies for patients with bladder cancer and other metastases.
Bacillus Calmette-Guérin (BCG) is an effective biologic therapy widely used in patients with non-muscle invasive bladder cancer. Sanofi recently announced their intent to discontinue BCG production, leaving Merck…
Julio A. Aguirre-Ghiso, PhD, Professor of Medicine, Hematology, and Medical Oncology at the Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, is leading a study on…
Immunotherapy with newly developed “immune checkpoint inhibitors” has led to striking advances in treatment for aggressive malignancies such as melanoma, non-small cell lung cancer, and renal cell carcinoma.…
New research is helping scientists better understand gene modification’s effects on many forms of bladder cancer. Additionally, results from numerous recent studies seem to foreshadow a change of…
NEW YORK (Reuters Health) – A diagnosis of bladder cancer after an initial presentation with hematuria is often delayed in both men and women – but the delay…
NEW YORK (Reuters Health) – An updated meta-analysis supports the strategy of giving intravesical chemotherapy (IVC) immediately after bladder tumor resection to reduce the risk of recurrence. “However,…
